Patients with autoimmune thyroid disease (AITD) show defects in their immune-regulatory mechanisms. Herein we assessed the expression and function CD150 in lymphocytes subpopulations from patients with AITD.
INTRODUCTION
Signalling lymphocytic activation molecule SLAMF1 (CD150) is a modulatory receptor expressed in most immune cells. Different data indicate that CD150 is involved in T cell cytokine production, NK cell and CD8 T cell mediated cytotoxicity, and T regulatory (Treg) cell activity.
PATIENTS AND METHODS
We analyzed by multi-parametric flow cytometry and immunofluorescence techniques the expression of SLAMF1 in peripheral blood from 28 patients with autoimmune thyroid disease (AITD) and 21 controls, and thyroid tissue cell infiltrates from 5 patients. We also assessed the functional role of SLAMF1 in CD4+CD25+ Treg cells, using an assay of inhibition of cellular proliferation
RESULTS

Figure 1:
Expression of SLAMF1 in lymphocytes from patients with AITD. PBMC from 28 AITD patients and 21 controls were isolated and stained with mAbs directed against CD4, CD8, CD19, CD56, CD16, CD25, Foxp3, IL-17 and SLAMF1. B and E horizontal lines correspond to mean and standard deviation and A, C, D, F-H correspond the median and Q1-Q3. *p<0.05, **p<0.01, ***p<0.005. 
CONCLUSIONS
The altered pattern of expression and the functional alteration of SLAMF1 found in patients with AITD suggests that SLAMF1 could be involved in the pathogenesis of AITD. Keywords: SLAMF1, CD150, Autoimmune Thyroiditis, Graves' Disease, Hashimotos' Thyroiditis. 
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